latest news releases from the newsroom
OrderPro Logistics Subsidiary TransMex Logistics Marks Anniversary
TUCSON, Ariz., Nov. 7, 2006 (PRIMEZONE) -- OrderPro Logistics, Inc. (Pink Sheets:OPLO) announced today that its subsidiary TransMex Logistics, through its president Ray F. Ascencio, marks its thirtieth year anniversary as a member of the IANA (Intermodal Association of North America). The Intermodal Association of North America (IANA) is the premier trade association representing the combined interests of the intermodal freight industry. IANA programs and services keep members informed of industry trends, crucial legislative and regulatory issues, and provide educational forums, networking opportunities, news and vital industry information.
Emulex Teams With VMware to Deliver Enhanced Storage Networking Capabilities
LOS ANGELES, Nov. 7, 2006 (PRIMEZONE) -- VMworld -- Emulex Corporation (NYSE:ELX) today announced the availability of its LightPulse(r) Virtual Host Bus Adapter (HBA) technology for VMware Infrastructure environments, delivering enhanced SAN management capabilities. The Emulex LightPulse Virtual HBA technology, available for use with its 4Gb/s family of Fibre Channel HBAs, allows end users to leverage SAN Best Practices when attaching virtual servers to networked storage.
National Stem Cell Holding, Inc.
Renowned Stem Cell and Diabetes Researcher Michael Shamblott Named Chief Scientific Advisor For National Stem Cell
NEW YORK, Nov. 7, 2006 (PRIMEZONE) -- National Stem Cell Holding, Inc. (Pink Sheets:NHGI), a biotech company based in New York, announced today that Michael J. Shamblott, Ph.D., a founding member of the Johns Hopkins University School of Medicine's Institute for Cell Engineering, has been named the company's Chief Scientific Advisor. In this new role, Dr. Shamblott will lead the National Stem Cell Scientific Advisory Board which was established to guide the research and development initiatives of the company.
Carthew Bay Technologies Inc.
Astris Energi Secures Fuel Cell Funding from Czech Republic Ministry of Industry
MISSISSAUGA, Ontario, Nov. 7, 2006 (PRIMEZONE) -- Astris Energi Inc. (OTCBB:ASRNF), announced today that Astris s.r.o., the wholly owned European subsidiary of Astris Energi Inc., received another grant from the Ministry of Industry and Trade (MPO) of the Czech Republic. This is the third grant awarded to Astris from the MPO. The funding will be used to subsidize Astris' fuel cell development efforts for backup power in the telecom industry at its Czech-based subsidiary.
CDMA Development Group
KDDI Continues to Lead by Implementing CDMA2000 Evolution Roadmap
COSTA MESA, Calif., Nov. 7, 2006 (PRIMEZONE) -- The CDMA Development Group (CDG) (www.cdg.org) today reported that KDDI is strengthening its technological and differentiated services lead in Japan by upgrading its CDMA2000(r) 1xEV-DO (CDMA 1X WIN) network to Rev A. This will enable KDDI to introduce delay sensitive applications, VoIP-based video telephony, and other real-time, symmetric and concurrent transmission voice and data applications with quality of service (QoS) features, while evolving its core network to a totally IP-based platform.
Energy Telecom, Inc.
Energy Telecom Announces the Awarding of U.S. Patent 7,133,532
MIAMI BEACH, Fla., Nov. 7, 2006 (PRIMEZONE) -- Energy Telecom, Inc. (Pink Sheets:EYTL), www.energytele.com) is pleased to announce that the United States Patent and Trademark Office has granted the company U.S. Patent 7,133,532. This forward-looking patent extends Energy's already firm protection of the first generation of true communication eyewear. This new patent's claims protect Energy Telecom and its partners, when their communication products deliver superior sound to the ear using sound attenuating ear pieces or plugs, to the inner ear canal, or through the outside perimeter of the canal opening.
BioCurex Discusses PSA Article from the Journal of the National Cancer Institute
RICHMOND, British Columbia, Nov. 7, 2006 (PRIMEZONE) -- BioCurex Inc. (OTCBB:BOCX) today commented on the PSA velocity study published on Nov. 1 in the Journal of the National Cancer Institute (NCI). In this study, the authors studied the increase of PSA ("velocity") in serum samples from 980 men monitored since 1958. The authors evaluated the association between PSA velocity and death from prostate cancer during the period of 10-15 years before diagnosis. The authors conclude that PSA velocity provides information early in the disease course that is related to the chance of dying of prostate cancer, before diagnosis, when PSA levels are below 4.0 ng/mL (the current threshold above which cancer is suspected), and at a time when cure might be still possible with local therapy (surgery or radiation). However, the authors make it clear that this is a possibility and not a fact as they add: "Thirdly, we cannot be certain that if a life-threatening prostate cancer had been identified by PSA velocity earlier in the natural history of the disease, treatment at that point in time would have changed the outcome. Rather, PSA velocity might identify men who are destined to succumb to their disease in spite of curative intervention."